Pfizer's Ibrance delays breast cancer progression: study

Pfizer's Ibrance delays breast cancer progression: study


Pfizer Inc's Ibrance in combination with another commonly-used drug kept advanced breast cancer in check significantly longer than the standard treatment alone in a late stage study, according to data released on Wednesday. Ibrance received an accelerated U.S. approval in February 2015 based on its ability to delay disease progression in an earlier, smaller Phase II clinical trial, with the condition that the results be replicated in a larger study in order to gain full approval.



from Biotech News